Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
DENTSPLY SIRONA Inc. director Betsy D. Holden reported an automatic share acquisition tied to her existing equity awards. On January 9, 2026, she acquired 710.956 shares of common stock at a price of $0, reflecting dividends on her restricted stock units (RSUs) that were paid in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying awards, and each RSU converts into one share of common stock. Following this transaction, Holden beneficially owned 54,613.852 shares of DENTSPLY SIRONA common stock in direct ownership.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported receiving additional equity-linked compensation. On 01/09/2026, he acquired 314.959 shares of common stock at a price of $0, reported as directly owned. After this transaction, he beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.
According to the footnote, these shares represent dividends on existing restricted stock units (RSUs), credited in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying RSU awards, vest simultaneously with them, and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. reported that senior vice president and chief human resources officer Andrea L. Frohning acquired additional equity-linked awards on January 9, 2026. She received 392.387 shares of common stock at a price of $0, described as dividends on restricted stock units that are credited as additional RSUs and vest on the same schedule as the underlying awards. After this, she beneficially owned 34,002.252 shares of common stock directly.
Frohning also acquired 22.7283 shares of phantom stock at $12.22 per unit under a Supplemental Executive Retirement Plan, bringing her total phantom stock holdings to 1,759.2738 units. Each phantom stock unit and each RSU is economically equivalent to one share of common stock, with phantom stock payable in common stock upon her termination of employment and RSUs converting into common stock on a 1:1 basis at vesting.
DENTSPLY SIRONA Inc. director Willie A. Deese reported an automatic stock-related transaction. On 01/09/2026, he acquired 201.508 shares of common stock at a price of $0. These shares represent dividends on previously granted restricted stock units (RSUs), paid in the form of additional RSUs that carry the same vesting schedule as the original awards.
Following this transaction, Deese directly beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock. Each RSU converts into one share of common stock on a 1:1 basis, and the dividend RSUs vest at the same time as the underlying RSUs they relate to.
DENTSPLY SIRONA Inc. VP and Chief Accounting Officer Kevin Czerney reported routine equity-related awards. On January 9, 2026, he acquired 262.7169 shares of common stock at $0, representing dividends paid in the form of additional restricted stock units that follow the same vesting schedule as the underlying RSUs, each converting into one share of common stock.
On the same date, he also acquired 4.0523 shares of phantom stock under the Dentsply Supplemental Savings Plan and 45.13 shares of phantom stock under the Supplemental Executive Retirement Plan at an economic value of $12.22 per phantom share, each economically equivalent to one share of common stock and payable in stock upon termination of employment. Following these transactions, his reported holdings increased to 28,040.786 shares of common stock, 341.201 phantom shares in the savings plan, and 3,493.4336 phantom shares in the retirement plan.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an automatic stock-related transaction. On 01/09/2026, he acquired 245.816 shares of common stock at a price of $0, bringing his directly held beneficial ownership to 17,944.987 shares.
The new shares come from dividends on restricted stock units (RSUs). These dividends were credited in the form of additional RSUs that follow the same vesting schedule as the original RSU awards. Each RSU converts into one share of common stock when it vests, so the reported amount reflects stock tied to his existing equity compensation rather than an open-market purchase.
DENTSPLY SIRONA Inc. reported that its Board of Directors, following a recommendation from the Corporate Governance and Nominating Committee, increased the size of the Board from 10 to 11 members, effective January 10, 2026.
On the same date, the Board appointed Donald J. Zurbay as a director, with his term running until the election of directors at the 2026 annual meeting of stockholders. He will also serve on the Board’s Audit and Finance Committee. The company notes that he has no family relationships with existing leaders and no material related-party transactions requiring disclosure. He will receive the same compensation as other non-employee directors. The company furnished, but did not file, a press release about his appointment as Exhibit 99.1.
DENTSPLY SIRONA Inc. director reports open-market stock purchase
A director of DENTSPLY SIRONA Inc. (XRAY) reported buying common stock in the company. On 11/24/2025, the reporting person purchased 9,337 shares of common stock at a price of $10.71 per share, in an open-market transaction coded as a purchase. After this transaction, the director beneficially owns 57,342.925 shares of DENTSPLY SIRONA common stock, held directly. This filing is a routine Form 4 disclosure of insider trading activity required under U.S. securities regulations.
DENTSPLY SIRONA Inc. reported a leadership update, appointing Michael Pomeroy as interim Chief Financial Officer effective November 25, 2025. He will serve in this temporary role while the company searches for a permanent Chief Financial Officer.
During this period, President and Chief Executive Officer Daniel T. Scavilla will continue to act as the company’s principal financial officer in addition to his role as principal executive officer. Pomeroy brings extensive finance leadership experience across industrial, healthcare, consumer, and distribution businesses, including prior CFO roles at Icahn Automotive Group, Hollander-Keeco, and RGIS, and a recent interim CFO role at spinal devices company Highridge Medical.
DENTSPLY SIRONA (XRAY) disclosed a Form 4 for an officer, SVP and Chief Supply Chain Office, reporting two stock option grants on 11/07/2025. The filings show awards of 417,200 options at an exercise price of $11.18 and 361,700 options at $12.3, each recorded as an acquisition (Code A) with $0 option price, indicating grants. Both grants are held directly and will cliff-vest on the third anniversary of the grant date (11/07/2028), with expiration on 11/07/2035. The second grant’s exercise price equals 110% of the issuer’s closing price on the grant date.